ClinicalTrials.gg
Enrolling by invitationNCT01654159Updated Jan 21, 2026

Assessment of Visual Function and Optics in Intraocular Lenses

An interventional study of Monofocal IOL and Multifocal IOL in Cataract, sponsored by Aston University. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Aston University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Cataract with a site in United Kingdom — 8 open to participants now, 8 under way, 1 of them phase 3. Cataract · United Kingdom.

Planned enrollment
2nd of 29
500 · median 100
Started
2013
with 2 others
No phase
23 of 39
4 open now
Registered
4th of 39
by date
Lead sponsor
1 of 39
Aston University

Among the 39 studies in Cataract with a site in United Kingdom, this one is the 2nd largest by planned enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2013, is one of 23 with no phase, and was the 4th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

8 of the 39 studies in Cataract with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Cataract with a site in United Kingdom, or all of them as a file.
02

Study summary

The main objective of this research is to assess visual function and optical performance of CE marked, implanted intraocular lenses to understand the individual factors that affect their performance and how these may be improved in future designs and to evaluate measurement techniques.

All outcome measures will be captured 3-6 months after surgery

Read the detailed description

A cataract occurs when the natural lens of the eye, which plays a major role in the focusing of light and production of sharp visual images, becomes cloudy and hardens, resulting in a loss of visual function. Left untreated, cataracts can cause preventable blindness. During cataract surgery the natural lens is removed and a man-made intraocular lens (IOL) is implanted in its place.

IOL technology has advanced significantly in recent years and as a result the main goal of cataract surgery is no longer simply the successful removal of the cloudy lens and restoration of vision. Providing patients with the best possible refractive outcome and the best possible visual quality is now much more important when assessing surgery outcomes.

Aspheric, multifocal and accommodating IOLs are among the new designs developed to improve visual outcome after cataract surgery. In order to assess the effectiveness of these designs, visual function needs to be evaluated both objectively and subjectively following their implantation. Such evaluation allows the continued evolution of these IOL designs towards optimum. This proposed research study, which aims to assess the visual function and optical performance of new CE marked IOLs after implantation, could significantly contribute to the enhancement and development of improved IOL designs in the future.

We have successfully conducted similar patient trials for the past 5 years. As new IOL designs are constantly being developed, approved and CE marked, this type of research study will always have the potential to offer new information that is not currently available and has not previously been assessed or published and could contribute towards improved IOL designs in the future.

All outcome measures will be captured 3-6 months after surgery

03

Conditions studied

  • Cataract

Browse trials for

Keywords

  • intraocular lenses
  • evaluation
  • cataract
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects age between 40-85 years, may be either male or female, and may be of any race (as cataracts rarely occur before the age of 40 and above 85 other ocular pathology is common).
  • Subjects requiring cataract surgery.
  • Potential for best corrected visual acuity of 6/12 or better (as visual function in these patients will be affected by ocular pathology).
  • Subjects with clear intraocular media other than cataract (as assessing cataract).
  • General physical and mental condition allowing participation in current study.
  • Subjects willing to participate as evidenced by signing the written informed

Exclusion criteria

Exclusion Criteria:

  • Prior surgery on the selected eye
  • Previous uveitis or trauma to the selected eye, anterior or posterior synechiae
  • Potential for best corrected visual acuity worse than 6/12 (since this may indicate other causes of ocular pathology)
  • Partial or total paralysis, Parkinsons syndrome, cerebrovascular accident or other condition that could impact on the results of the study
  • Subject over 85 years of age (ocular pathology more common in this age group)
  • Subjects without adequate physical and mental capacity to enable participation in the study
  • Subject unwilling to participate
  • Systemic or topical medication known to influence visual function measures
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
500 participants (estimated)

Study arms

  • Placebo comparator
    Monofocal

    Monofocal IOL Implant Manufacturers of IOLs used as monofocal comparator are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss

    Procedure: Monofocal IOL

  • Experimental
    Multifocal

    Multifocal IOL Manufacturers of multifocal IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss

    Procedure: Multifocal IOL

  • Experimental
    Toric

    Toric IOL Manufacturers of toric IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss

    Procedure: Toric IOL

Interventions

  • ProcedureMonofocal IOL

    Monofocal Intraocular lens will be implanted

    Also known as: Alcon AMO B&L Lenstec Oculentis Ophthec Physiol & Zeiss

  • ProcedureMultifocal IOL

    Multifocal IOL will be implanted

  • ProcedureToric IOL

    Toric IOLS will be implanted

06

What researchers measure

Primary outcomes

  1. Unaided distance and near vision

    Visual Acuity (logMAR)

    Time frame: Measured at 3-6 months after surgery

Secondary outcomes

  1. Patient Satisfaction

    NAVQ score

    Time frame: Measured at 3-6 months after surgery

  2. Residual refraction

    Autorefraction / subjective refraction

    Time frame: Measured at 3-6 months after surgery

  3. Aberrations

    Aberrometry

    Time frame: Measured at 3-6 months after surgery

  4. Corrected distance and near acuity

    Acuity (logMAR)

    Time frame: Measured at 3-6 months after surgery

07

Study locations

1 site
  • Birmingham Midland Eye Centre
    Birmingham, West Midlands B18 7QH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Data collaboration will be considered on request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2013 (actual). Primary completion is estimated for Nov 2030, 206 months after the start.

Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 206 months is above that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2012
First posted
Jul 31, 2012
StartActual
Sep 2013
Primary completionEst.
Nov 30, 2030
CompletionEst.
Nov 30, 2030
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01654159
Lead sponsor
Aston University
Responsible party
Sponsor
First posted
Jul 31, 2012
Start date
Sep 2013
Primary completion
Nov 30, 2030 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Jan 21, 2026

Study contacts

Sunil Shah, FRCS
principal investigator · Birmingham Midland Eye Centre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion